Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Human Rabies Immunoglobulin (IM) Market by Type (ERIG, HRIG), By Application (Category II Exposure, Category III Exposure) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Human Rabies Immunoglobulin (IM) Market by Type (ERIG, HRIG), By Application (Category II Exposure, Category III Exposure) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 138192 3300 Pharma & Healthcare 377 242 Pages 4.6 (31)

Market Overview:

The global human rabies immunoglobulin (IM) market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of rabies and rising demand for human rabies immunoglobulin (IM) products. Rabies is a viral disease that affects the central nervous system and is fatal if not treated immediately. The increasing awareness about the availability of post-exposure prophylaxis (PEP) for rabies has led to an increase in demand for human rabies immunoglobulin (IM). The global human rabies immunoglobulin (IM) market can be segmented on the basis of type, application, and region. On the basis of type, the market can be divided into ERIG and HRIG. ERIG dominates this market owing to its high efficacy and long shelf life as compared to HRIG products. On the basis of application, this market can be classified into category II exposure and category III exposure segments.

Global Human Rabies Immunoglobulin (IM) Industry Outlook

Product Definition:

Human Rabies Immunoglobulin (IM) is a preparation of antibodies which are used to prevent rabies. The antibodies in the immunoglobulin help to protect an individual from the rabies virus. It is important for individuals who may be exposed to the rabies virus to receive this immunization as soon as possible.


The European Rabbit Irrigation Water (ERIH) is a novel water resource developed for irrigation of animal feed. It consists of high mineral content and has been used successfully to grow meat rabbits. The product also helps in reducing the cost associated with rabbit food, thereby making it affordable for developing countries like India and China where consumption patterns are changing due to rising disposable income.


HRIG, also known as human rabies immunoglobulin, is a vaccine therapy used to prevent people from getting rabies. IM has several advantages over the conventional vaccines such as plasma-based vaccines and inactivated virus vaccines. The main advantage of HRIG is that it provides protection against all forms of rabies including Lyssaviruses which are generally more harmful than other variants.

Application Insights:

The Category II exposure segment dominated the global market in 2017. The major application of human rabies immunoglobulin is for post-exposure prophylaxis of humans against rabies. According to WHO, approximately 60% to 90% of people exposed to rabid animals develop symptoms within one year; however, only 10% or less die from the disease if given immediate treatment. IM administration has been found effective in preventing mortality and neurologic disability associated with this infection in humans.

Rabies post-exposure prophylaxis (PEP) is an effective intervention for prevention against rabies when given within three days of potential exposure and prior to development of clinical symptoms among susceptible individuals, as per guidelines laid down by WHO & CDC.

Regional Analysis:

Asia Pacific dominated the global market in 2017. The presence of a large number of animal rabies reservoirs, coupled with high human population density in this region, is expected to drive the demand for HRIG over the forecast period. In addition, increasing travel and trade activities across countries with high and low human rabies incidence are further anticipated to fuel product demand.

The Asia Pacific was followed by Europe which accounted for over 25% of total revenue share in 2017 owing to growing awareness about potential benefits associated ERIG therapy along with rising R&D initiatives undertaken by major players operating in this space. North America also held a significant share due to early adoption of immunoglobulin based therapies as compared to other regions despite lacklustre reimbursement scenario post-marketing surveillance studies conducted on humans have shown that IMs are safe when used appropriately (category II or III) exposure).

Growth Factors:

  • Increasing incidence of rabies across the globe
  • Growing awareness about the benefits of human rabies immunoglobulin (IM) therapy
  • Rising demand for human rabies immunoglobulin (IM) from emerging markets
  • Technological advancements in the manufacturing of human rabies immunoglobulin (IM) products
  • increasing number of research and development activities focused on human rabies immunoglobulin (IM)

Scope Of The Report

Report Attributes

Report Details

Report Title

Human Rabies Immunoglobulin (IM) Market Research Report

By Type


By Application

Category II Exposure, Category III Exposure

By Companies

CSL Behring, Grifols , Sanofi, Sichuan Yuanda Shuyang, CNBG, Kamada, CBPO, Shuanglin Bio, Weiguang Bio, Shanghai RAAS, Bharat Serum, VINS

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year


Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year


Number of Pages


Number of Tables & Figures


Customization Available

Yes, the report can be customized as per your need.

Global Human Rabies Immunoglobulin (IM) Market Report Segments:

The global Human Rabies Immunoglobulin (IM) market is segmented on the basis of:



The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.


Category II Exposure, Category III Exposure

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. CSL Behring
  2. Grifols 
  3. Sanofi
  4. Sichuan Yuanda Shuyang
  5. CNBG
  6. Kamada
  7. CBPO
  8. Shuanglin Bio
  9. Weiguang Bio
  10. Shanghai RAAS
  11. Bharat Serum
  12. VINS

Global Human Rabies Immunoglobulin (IM) Market Overview

Highlights of The Human Rabies Immunoglobulin (IM) Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. ERIG
    2. HRIG
  1. By Application:

    1. Category II Exposure
    2. Category III Exposure
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Human Rabies Immunoglobulin (IM) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Human Rabies Immunoglobulin (IM) Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?

Human rabies immunoglobulin (IM) is a protein that helps the body fight off rabies.

Some of the key players operating in the human rabies immunoglobulin (im) market are CSL Behring, Grifols‚ , Sanofi, Sichuan Yuanda Shuyang, CNBG, Kamada, CBPO, Shuanglin Bio, Weiguang Bio, Shanghai RAAS, Bharat Serum, VINS.

The human rabies immunoglobulin (im) market is expected to register a CAGR of 5.5%.

1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Human Rabies Immunoglobulin (IM) Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Human Rabies Immunoglobulin (IM) Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Human Rabies Immunoglobulin (IM) Market - Supply Chain
   4.5. Global Human Rabies Immunoglobulin (IM) Market Forecast
      4.5.1. Human Rabies Immunoglobulin (IM) Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Human Rabies Immunoglobulin (IM) Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Human Rabies Immunoglobulin (IM) Market Absolute $ Opportunity

5. Global Human Rabies Immunoglobulin (IM) Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Type
      5.3.1. ERIG
      5.3.2. HRIG
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Human Rabies Immunoglobulin (IM) Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Application
      6.3.1. Category II Exposure
      6.3.2. Category III Exposure
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Human Rabies Immunoglobulin (IM) Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Human Rabies Immunoglobulin (IM) Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Human Rabies Immunoglobulin (IM) Demand Share Forecast, 2019-2029

9. North America Human Rabies Immunoglobulin (IM) Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Application
      9.4.1. Category II Exposure
      9.4.2. Category III Exposure
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Type
      9.7.1. ERIG
      9.7.2. HRIG
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Human Rabies Immunoglobulin (IM) Demand Share Forecast, 2019-2029

10. Latin America Human Rabies Immunoglobulin (IM) Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Application
      10.4.1. Category II Exposure
      10.4.2. Category III Exposure
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Type
      10.7.1. ERIG
      10.7.2. HRIG
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Human Rabies Immunoglobulin (IM) Demand Share Forecast, 2019-2029

11. Europe Human Rabies Immunoglobulin (IM) Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Application
      11.4.1. Category II Exposure
      11.4.2. Category III Exposure
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Type
      11.7.1. ERIG
      11.7.2. HRIG
   11.8. Basis Point Sare (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Human Rabies Immunoglobulin (IM) Demand Share, 2019-2029

12. Asia Pacific Human Rabies Immunoglobulin (IM) Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Application
      12.4.1. Category II Exposure
      12.4.2. Category III Exposure
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Type
      12.7.1. ERIG
      12.7.2. HRIG
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Human Rabies Immunoglobulin (IM) Demand Share, 2019-2029

13. Middle East & Africa Human Rabies Immunoglobulin (IM) Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Application
      13.4.1. Category II Exposure
      13.4.2. Category III Exposure
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Human Rabies Immunoglobulin (IM) Market Size and Volume Forecast by Type
      13.7.1. ERIG
      13.7.2. HRIG
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Human Rabies Immunoglobulin (IM) Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Human Rabies Immunoglobulin (IM) Market: Market Share Analysis
   14.2. Human Rabies Immunoglobulin (IM) Distributors and Customers
   14.3. Human Rabies Immunoglobulin (IM) Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. CSL Behring Overview Financials Developments Strategic Outlook
      14.4.2. Grifols  Overview Financials Developments Strategic Outlook
      14.4.3. Sanofi Overview Financials Developments Strategic Outlook
      14.4.4. Sichuan Yuanda Shuyang Overview Financials Developments Strategic Outlook
      14.4.5. CNBG Overview Financials Developments Strategic Outlook
      14.4.6. Kamada Overview Financials Developments Strategic Outlook
      14.4.7. CBPO Overview Financials Developments Strategic Outlook
      14.4.8. Shuanglin Bio Overview Financials Developments Strategic Outlook
      14.4.9. Weiguang Bio Overview Financials Developments Strategic Outlook
      14.4.10. Shanghai RAAS Overview Financials Developments Strategic Outlook
      14.4.11. Bharat Serum Overview Financials Developments Strategic Outlook
      14.4.12. VINS Overview Financials Developments Strategic Outlook
      14.4.13. COMPANY 13 Overview Financials Developments Strategic Outlook
      14.4.14. COMPANY 14 Overview Financials Developments Strategic Outlook
      14.4.15. COMPANY 15 Overview Financials Developments Strategic Outlook
      14.4.16. COMPANY 16 Overview Financials Developments Strategic Outlook
      14.4.17. COMPANY 17 Overview Financials Developments Strategic Outlook
      14.4.18. COMPANY 18 Overview Financials Developments Strategic Outlook
      14.4.19. COMPANY 19 Overview Financials Developments Strategic Outlook
      14.4.20. COMPANY 20 Overview Financials Developments Strategic Outlook

Our Trusted Clients

Contact Us